IPF Patients and Doctors Looking for New Treatment Options

IPF Patients and Doctors Looking for New Treatment Options
0
(0)

pf_ipf doctors

Spherix Global Insights, GmbH, a business intelligence and market research company based in Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially since the majority of patients are diagnosed at already advanced disease stages. The Spherix study is entitled “Market Dynamix: Idiopathic Pulmonary Fibrosis (IPF).”

Currently, there are two approved drugs for IPF treatment: Esbriet (pirfenidone), developed by Roche, and Ofev (nintedanib), developed by Boehringer Ingelheim. Several companies are exploring potential new therapies, including MediciNova (tipelukast), Biogen (STX-100), Gilead (simtuzumab), Afferent (AF-219), and FibroGen (FG-3019). However, according to a Spherix press release, physicians are not well-informed concerning future therapeutic options for IPF and the potential benefits they may offer.

Read more about it: http://bit.ly/22MCruQ

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *